MEDIPOST closed on $140 million in funding to accelerate a U.S. Phase III clinical trial of investigational mesenchymal stem cell (MSC) therapy in the treatment of symptomatic cartilage defects in patients with knee osteoarthritis. The company seeks to expand scientific and operational capabilities, build infrastructure, and scale manufacturing processes.
Umbilical cord blood-derived stem cell therapies bring together biologically young cells, immune tolerance and scalable manufacturing, underscoring the innovation and long-term promise of regenerative medicine as a rapidly advancing field.
“The funding from Korea’s top growth equity funds fuels MEDIPOST’s global expansion as we prepare to advance into Phase III clinical evaluation in the U.S., with trial initiation anticipated in early 2026,” said Edward Ahn, PhD, Chief Executive Officer of MEDIPOST Inc. “It allows us to move into late-stage development while continuing to build the clinical, operational and manufacturing foundation needed to bring scalable, off-the-shelf regenerative therapies closer to patients.”
MEDIPOST closed on $140 million in funding to accelerate a U.S. Phase III clinical trial of investigational mesenchymal stem cell (MSC) therapy in the treatment of symptomatic cartilage defects in patients with knee osteoarthritis. The company seeks to expand scientific and operational capabilities, build infrastructure, and scale manufacturing...
MEDIPOST closed on $140 million in funding to accelerate a U.S. Phase III clinical trial of investigational mesenchymal stem cell (MSC) therapy in the treatment of symptomatic cartilage defects in patients with knee osteoarthritis. The company seeks to expand scientific and operational capabilities, build infrastructure, and scale manufacturing processes.
Umbilical cord blood-derived stem cell therapies bring together biologically young cells, immune tolerance and scalable manufacturing, underscoring the innovation and long-term promise of regenerative medicine as a rapidly advancing field.
“The funding from Korea’s top growth equity funds fuels MEDIPOST’s global expansion as we prepare to advance into Phase III clinical evaluation in the U.S., with trial initiation anticipated in early 2026,” said Edward Ahn, PhD, Chief Executive Officer of MEDIPOST Inc. “It allows us to move into late-stage development while continuing to build the clinical, operational and manufacturing foundation needed to bring scalable, off-the-shelf regenerative therapies closer to patients.”
Copy to clipboard 
